GameChangers: Dupilumab in COPD
GameChangers: Dupilumab in COPD
A new biologic agent, Dupilimab, may be a possible treatment for chronic obstructive pulmonary disorder. Join host, Geoff Wall, as he evaluates the use of dupilimab in COPD with Type 2 inflammation
THE GAMECHANGER: Type 2 inflammation is driven by eosinophils and IL-4, 5, and 11. It occurs in 20% of patients with COPD. Dupilimab was able to decrease COPD exacerbations by 50% and improve symptoms
Upon successful completion of this course, learners should be able to:
1. Discuss the different phenotypes of COPD and treatment options
2. Describe the BOREAS trial and the applicability to patients with COPD
Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences
Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: August 21, 2023
Planned Expiration Date: August 21, 2024
Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Additional information
| Duration | 0h 30m |
|---|---|
| Topic Designator | Disease State/Drug Therapy |
| ACPE | Yes |
| ACPE Topic | |
| Role | Pharmacist |
| Media-Type | Podcast |
| Release Date | 8/21/23 |
| CEUs | 0.05 |
| Rating | 4 |
| ACPE Number | 0107-0000-23-288-H01-P |
